Pulmatrix, Inc. (NASDAQ:PULM) Sees Significant Increase in Short Interest

Posted by Brenda Bartman on Sep 11th, 2026

Pulmatrix, Inc. (NASDAQ:PULM – Get Free Report) was the target of a significant increase in short interest in the month of August. As of August 31st, there was short interest totaling 20,198 shares, an increase of 384.2% from the August 15th total of 4,171 shares. Based on an average trading volume of 12,801 shares, the days-to-cover ratio is currently 1.6 days. Approximately 0.6% of the company’s shares are short sold.

Pulmatrix Trading Down 1.7%

PULM traded down $0.03 on Friday, reaching $1.44. The stock had a trading volume of 5,674 shares, compared to its average volume of 41,472. The company has a market cap of $5.24 million, a P/E ratio of -1.30 and a beta of 1.90. Pulmatrix has a 12-month low of $1.16 and a 12-month high of $5.50. The business’s 50-day moving average price is $1.60 and its two-hundred day moving average price is $1.61.

Pulmatrix (NASDAQ:PULM – Get Free Report) last announced its earnings results on Thursday, August 13th. The biotechnology company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.00) by $1.71.

Institutional Investors Weigh In On Pulmatrix

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Dimensional Fund Advisors LP acquired a new position in Pulmatrix in the third quarter valued at $52,000. DRW Securities LLC purchased a new position in shares of Pulmatrix in the 4th quarter valued at about $46,000. Finally, BlackRock Inc. acquired a new stake in shares of Pulmatrix during the 2nd quarter valued at approximately $93,000. 11.84% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, Weiss Ratings downgraded shares of Pulmatrix from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, August 14th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, Pulmatrix has a consensus rating of “Sell”.

Get Our Latest Report on Pulmatrix

Pulmatrix Company Profile

(Get Free Report)

Pulmatrix, Inc is a clinical-stage biopharmaceutical company dedicated to developing inhaled therapies for patients suffering from respiratory diseases. The company’s proprietary iSPERSE® dry-powder formulation platform produces fine microparticles optimized for deep-lung delivery, rapid absorption and consistent dosing, addressing challenges often encountered with traditional inhalation approaches.

Among Pulmatrix’s lead programs is PUR1900, an inhaled therapy designed to treat pulmonary fungal infections such as allergic bronchopulmonary aspergillosis (ABPA).